Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.

Kim, Sa Rang; Charos, Alexandra; Damsky, William; Heald, Peter; Girardi, Michael; King, Brett A

Kim, Sa Rang; Charos, Alexandra; Damsky, William; Heald, Peter; Girardi, Michael; King, Brett A.

Afiliación

Kim SR; Yale School of Medicine, New Haven, Connecticut.
Charos A; Yale School of Medicine, New Haven, Connecticut.
Damsky W; The Department of Dermatology, Yale University, New Haven, Connecticut.
Heald P; The Department of Dermatology, Yale University, New Haven, Connecticut.
Girardi M; The Department of Dermatology, Yale University, New Haven, Connecticut.
King BA; The Department of Dermatology, Yale University, New Haven, Connecticut.

JAAD Case Rep ; 4(5): 443-445, 2018 Jun.

Article en En | MEDLINE | ID: mdl-29984277

Palabras clave

ECP, extracorporeal photopheresis; EF, eosinophilic fasciitis; GDM, generalized deep morphea; HES, hypereosinophilic syndrome; IL, interleukin; JAK, Janus kinase; JAK-STAT; Janus kinase; Janus kinase inhibitor; ROM, range of motion; TGF-ß, transforming growth factor beta; eosinophilic fasciitis; interleukin-4; morphea; tofacitinib; transforming growth factor-ß

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: JAAD Case Rep Año: 2018 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google